Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Medway Data Falsification Was Organized: Committee Report
April 19, 2010
- 48% Fewer Deaths with Ticagrelor than Clopidogrel
April 19, 2010
- Mr Chofuku Urges Makers to Explain Meaning of New Premium to Med. Institutions
April 19, 2010
- Gov't Considers Health/Nursing Care, Drugs as Growth Drivers: Mr Nagatsuma
April 19, 2010
- Korosho to Encourage Switching of Ethical Drugs to OTC Status: Mr Nagatsuma
April 19, 2010
- Remicade Ranked No.1 on HP Market
April 19, 2010
- Cautious Discussions Necessary on Lifting of Ban on Kongo Shinryo: Mr Nagatsuma
April 19, 2010
- JACDS Calls For Continued Discussions on Online Sale of Drugs
April 19, 2010
- Taizhou City Invites Japanese Pharmas to Invest
April 19, 2010
- Arixtra Applied for Treatment of Acute DVT, PE: GSK
April 19, 2010
- JPA Supports Court Decision on Online Sale of Drugs: VP Idei
April 19, 2010
- Nippon Shinyaku Licenses Once-Daily Tramadol from Labopharm
April 19, 2010
- Fulvestrant Approved at 500 mg in EU: AZ
April 19, 2010
- RDKK Launches Elecsys Reagent for RA
April 19, 2010
- Zeria Licenses Hemostatic, Wound Dressing Agents from HemCon
April 19, 2010
- Afinitor, Temodal Transiently Excluded from DPC Payment System
April 19, 2010
- Kobayashi Pharm. Spins Off Medical Device Division
April 19, 2010
- Bayer Integrates Intendis
April 19, 2010
- Requirements for Med Institutions Conducting Regenerative Medicine Notified
April 19, 2010
- Medwatcher Japan Presents Petition on Use of Unapproved Medical Devices
April 19, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…